Effect of cigarette smoking on CYP2C9 activity.

被引：2
|
作者：
Kim, M
LaCourse, J
Nafziger, AN
Wallace, AL
Kashuba, AD
Rowland, E
Gaedigk, A
Bertino, JS
机构：
[1] Bassett Healthcare, Cooperstown, NY USA
[2] Univ N Carolina, Chapel Hill, NC 27515 USA
[3] Childrens Mercy Hosp, Cooperstown, NY USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2003年 / 73卷 / 02期
关键词：
D O I：
10.1016/S0009-9236(03)90407-3
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P14 / P14
页数：1
相关论文
共 50 条
  • [21] Functional characterization of the defective CYP2C9 variant CYP2C9*18
    Liu, Jian
    Chen, Hao
    Wang, Shuang-Hu
    Zhou, Quan
    Geng, Pei-Wu
    Zhou, Yun-Fang
    Wu, Hua-Lan
    Shi, Hai-Feng
    Wang, Fang
    Yang, Jie-Fu
    Cai, Jian-Ping
    Dai, Da-Peng
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (01):
  • [22] Echinacea alters CYP2C9 activity in vivo
    Gorski, JC
    Huang, SM
    Pinto, A
    Miller, P
    Desai, M
    Hall, SD
    DRUG METABOLISM REVIEWS, 2002, 34 : 131 - 131
  • [23] EFFECT OF CYP2C9 GENOTYPE AND EFAVIREZ ON CYP2CP ACTIVITY IN HEALTHY VOLUNTEERS
    Metzger, I. F.
    Lu, J. B.
    Thong, N.
    Skaar, T. C.
    Philips, S.
    Flockhart, D. A.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S80 - S80
  • [24] Effect of iguratimod on diclofenac metabolism by CYP2C9 in rats and human recombinant CYP2C9 yeast cells
    Usman, Muhammad
    Zhen-Han, Zhu
    Ze-Na, Chang
    Jun-Ping, Han
    Wen, Qian
    Chang-Qing, Yang
    Miyu, Nishikawa
    Toshiyuki, Sakaki
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 55
  • [25] Functional impact of CYP2C*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans
    Allabi, AC
    Gala, JL
    Horsmans, Y
    Babaoglu, MO
    Bozkurt, A
    Heusterspreute, M
    Yasar, U
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) : 113 - 118
  • [26] Mechanistic insights into the effect of CYP2C9*2 and CYP2C9*3 variants on the 7-hydroxylation of warfarin
    Pavani, Addepalli
    Naushad, Shaik Mohammad
    Stanley, Balraj Alex
    Kamakshi, Renganathan Gnanambal
    Abinaya, Krishnan
    Rao, Malempati Amaresh
    Uma, Addepally
    Kutala, Vijay Kumar
    PHARMACOGENOMICS, 2015, 16 (04) : 393 - 400
  • [27] Effect of fluvastatin on CYP2C9 activity using warfarin as a probe.
    Kim, M
    Nafziger, AN
    Kirchheiner, J
    Bauer, S
    Gaedigk, A
    Bertino, JS
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P28 - P28
  • [28] Inhibitory Effect of Apigenin on Losartan Metabolism and CYP2C9 Activity in vitro
    Wang, Zhe
    Gong, Yun
    Zeng, Da-li
    Chen, Lian-guo
    Lin, Gao-tong
    Huang, Cheng-ke
    Sun, Wei
    Chen, Meng-Chun
    Hu, Guo-xin
    Chen, Rui-jie
    PHARMACOLOGY, 2016, 98 (3-4) : 183 - 189
  • [29] An identification and functional evaluation of a novel CYP2C9 variant CYP2C9*62
    Chen, Hao
    Dai, Da-Peng
    Zhou, Shan
    Liu, Jian
    Wang, Shuang-Hu
    Wu, Hua-Lan
    Zhou, Quan
    Geng, Pei-Wu
    Chong, Jia
    Lu, You
    Cai, Jian-Ping
    Yang, Jie-Fu
    CHEMICO-BIOLOGICAL INTERACTIONS, 2020, 327
  • [30] Frequency of CYP2C9 variant alleles, including CYP2C9*13 in a Korean population and effect on glimepiride pharmacokinetics
    Lee, H. W.
    Lim, M. -S.
    Lee, J.
    Jegal, M. -Y.
    Kim, D. -W.
    Lee, W. -K.
    Jang, I. -J.
    Shin, J. -G.
    Yoon, Y. -R.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (01) : 105 - 111
12345